Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition and reactivation of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Exp Med
Главные авторы: Saei, Azad, Palafox, Marta, Benoukraf, Touati, Kumari, Nishi, Jaynes, Patrick William, Iyengar, Prasanna Vasudevan, Muñoz-Couselo, Eva, Nuciforo, Paolo, Cortés, Javier, Nötzel, Christopher, Kumarakulasinghe, Nesaretnam Barr, Richard, John Lalith Charles, Bin Adam Isa, Zul Fazreen, Pang, Brendan, Guzman, Marta, Siqin, Zhou, Yang, Henry, Tam, Wai Leong, Serra, Violeta, Eichhorn, Pieter Johan Adam
Формат: Artigo
Язык:Inglês
Опубликовано: Rockefeller University Press 2018
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6028519/
https://ncbi.nlm.nih.gov/pubmed/29880484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20171960
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы